Home » Stocks » SESN

Sesen Bio, Inc. (SESN)

Stock Price: $2.37 USD -0.12 (-4.82%)
Updated May 12, 2021 4:00 PM EDT - Market closed
After-hours: $2.43 +0.06 (2.53%) May 12, 6:23 PM
Market Cap 431.48M
Revenue (ttm) 15.55M
Net Income (ttm) -119.47M
Shares Out 157.03M
EPS (ttm) -0.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 12
Last Price $2.37
Previous Close $2.49
Change ($) -0.12
Change (%) -4.82%
Day's Open 2.40
Day's Range 2.36 - 2.51
Day's Volume 3,804,398
52-Week Range 0.62 - 3.57

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported opera...

2 days ago - Business Wire

Hot penny stocks to watch this month. The post Penny Stocks To Watch For May 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other stocks mentioned: ALF, TRVG
3 days ago - PennyStocks

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the ...

1 week ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that...

1 week ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported the g...

3 weeks ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it w...

1 month ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that...

1 month ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that...

1 month ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported opera...

1 month ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, announced that on Fr...

2 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that...

2 months ago - Business Wire

The FDA accepted the company's filing for approval of Vicineum in treating bladder cancer.

2 months ago - The Motley Fool

Hepion Pharmaceuticals (NASDAQ: HEPA) shares are trading lower Tuesday after the company priced its 44.2 million share common stock offering at $2 per share. Hepion Pharmaceuticals Inc is engaged in the...

2 months ago - Benzinga

Under priority review status, the FDA has accepted Sesen Bio Inc's (NASDAQ: SESN) marketing application for review seeking approval for Vicineum for the treatment of high-risk, BCG-unresponsive non-musc...

2 months ago - Benzinga

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, announced today that...

2 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that...

3 months ago - Business Wire

Sesen Bio (SESN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

3 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported that ...

3 months ago - Business Wire

An analyst is very bullish about the biotech stock.

3 months ago - The Motley Fool

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported that ...

3 months ago - Business Wire

Investors need to pay close attention to Sesen Bio (SESN) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced subm...

4 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced favo...

4 months ago - Business Wire

Sesen Bio (SESN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

5 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that...

5 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, and Hikma Pharmaceut...

5 months ago - Business Wire

Sesen Bio, Inc. (SESN) CEO Thomas Cannell On Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Sesen Bio, Inc.'s (SESN) CEO Thomas Cannell on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported opera...

6 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that...

6 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that...

6 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that ...

6 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it w...

8 months ago - Business Wire

Sesen Bio (SESN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

8 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported opera...

9 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--August 5, 2020 – Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, tod...

9 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, and Qilu Pharmaceuti...

9 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that...

9 months ago - Business Wire

Sesen Bio, Inc. (SESN) CEO Dr.

1 year ago - Seeking Alpha

Sesen Bio's (SESN) CEO Thomas Cannell on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Sesen Bio: Growing A Position Through The Rolling BLA Summary

1 year ago - Seeking Alpha

Sesen Bio With High Probability FDA Approval Upcoming

1 year ago - Seeking Alpha

Sesen Bio's (SESN) CEO Thomas Cannell on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

ENZN trades at all time highs, adjusted for dividends, and double the "base case" of the liquidation value.

Other stocks mentioned: ENZN
1 year ago - Seeking Alpha

The company reported a positive data update from the Phase 3 VISTA trial for BCG refractory high-grade NMIBC patients.

1 year ago - Seeking Alpha

Sesen plunged 35% after announcing a stock offering.

1 year ago - Seeking Alpha

Investors need to pay close attention to Sesen Bio (SESN) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

The stock more than doubled within the past two months.

1 year ago - Seeking Alpha

Sesen Bio (SESN) needs investors to pay close attention to the stock based on moves in the options market lately.

1 year ago - Zacks Investment Research

The company meets with the FDA on May 20 to discuss manufacturing aspects.

1 year ago - Seeking Alpha

About SESN

Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. The company's lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule (EpCAM)... [Read more...]

Industry
Biotechnology
IPO Date
Feb 6, 2014
CEO
Thomas Cannell
Employees
27
Stock Exchange
NASDAQ
Ticker Symbol
SESN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Sesen Bio stock is "Strong Buy." The 12-month stock price forecast is 7.00, which is an increase of 195.36% from the latest price.

Price Target
$7.00
(195.36% upside)
Analyst Consensus: Strong Buy